Alterations of the immune system in thymic malignancies

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages S137-S142

  Weksler, Benny ^a   Lu, Binfeng ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disorders; Immunology; Thymic carcinoma; Thymoma; Thymus

Indexed keywords

ARTICLE; AUTOIMMUNITY; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; PRIORITY JOURNAL; THEORY; THYMOMA; THYMUS; THYMUS CANCER; IMMUNOLOGY; PATHOLOGY;

HUMANS; THYMOMA; THYMUS NEOPLASMS;

EID: 84964314846     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000299     Document Type: Article

References (58)

1. Kondo K, Monden Y. Thymoma and myasthenia gravis: A clinical study of 1, 089 patients from Japan. Ann Thorac Surg 2005;79:219-224.
2. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001;50:64-72.
3. Nenninger R, Schultz A, Hoffacker V, et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998;78:743-753.
4. Anderson G, Jenkinson EJ. Lymphostromal interactions in thymic development and function. Nat Rev Immunol 2001;1:31-40.
5. Duijvestijn AM, Hoefsmit EC. Ultrastructure of the rat thymus: The micro-environment of T-lymphocyte maturation. Cell Tissue Res 1981;218:279-292.
6. Murata S, Sasaki K, Kishimoto T, et al. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 2007;316:1349-1353.
7. Gommeaux J, Grégoire C, Nguessan P, et al. Thymus-specific serine protease regulates positive selection of a subset of CD4+ thymocytes. Eur J Immunol 2009;39:956-964.
8. Viret C, Lamare C, Guiraud M, et al. Thymus-specific serine protease contributes to the diversification of the functional endogenous CD4 T cell receptor repertoire. J Exp Med 2011;208:3-11.
9. Nakagawa T, Roth W, Wong P, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280: 450-453.
10. Honey K, Nakagawa T, Peters C, Rudensky A. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: A role in the generation of positively selecting peptide ligands. J Exp Med 2002;195:1349-1358.
11. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003;21:139-176.
12. Hubert FX, Kinkel SA, Davey GM, et al. Aire regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. Blood 2011;118:2462-2472.
13. Anderson MS, Su MA. Aire and T cell development. Curr Opin Immunol 2011;23:198-206.
14. Guerau-de-Arellano M, Mathis D, Benoist C. Transcriptional impact of Aire varies with cell type. Proc Natl Acad Sci U S A 2008;105: 14011-14016.
15. Gäbler J, Arnold J, Kyewski B. Promiscuous gene expression and the developmental dynamics of medullary thymic epithelial cells. Eur J Immunol 2007;37:3363-3372.
16. Gray D, Abramson J, Benoist C, Mathis D. Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire. J Exp Med 2007;204:2521-2528.
17. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med 2005;202:901-906.
18. Akiyama T, Maeda S, Yamane S, et al. Dependence of self-Tolerance on TRAF6-directed development of thymic stroma. Science 2005;308:248-251.
19. Kajiura F, Sun S, Nomura T, et al. NF-kappa B-inducing kinase establishes self-Tolerance in a thymic stroma-dependent manner. J Immunol 2004;172:2067-2075.
20. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol 2007;19:176-185.
21. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In Kleihues P, Sobin LH(Eds.), World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2004. Pp. 147-249.
22. Ströbel P, Murumägi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007;211: 563-571.
23. Ströbel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: A retrospective analysis. J Clin Oncol 2004;22:1501-1509.
24. Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010;43:413-427.
25. Choi Decroos E, Hobson-Webb LD, Juel VC, Massey JM, Sanders DB. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve 2014;49:30-34.
26. McKeon A, Lennon VA, LaChance DH, Klein CJ, Pittock SJ. Striational antibodies in a paraneoplastic context. Muscle Nerve 2013;47: 585-587.
27. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006;81:2328-2334.
28. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: A retrospective analysis of 40 cases. Cancer 2002;94: 3115-3119.
29. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY. Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: A 20-year experience at a single institution. Eur J Cardiothorac Surg 2009;36:159-162.
30. Yano M, Sasaki H, Yokoyama T, et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008;3:265-269.
31. Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg 2012;93:1668-1672.
32. Liu HC, Hsu WH, Chen YJ, et al. Primary thymic carcinoma. Ann Thorac Surg 2002;73:1076-1081.
33. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115: 303-308.
34. Filosso PL, Guerrera F, Rendina AE, et al. Outcome of surgically resected thymic carcinoma: A multicenter experience. Lung Cancer 2014;83:205-210.
35. Yen YT, Lai WW, Chang KW, et al. Factors predicting recurrence and postrecurrence survival in completely resected thymic carcinoma. Ann Thorac Surg 2014;97:1169-1175.
36. Yen YT, Lai WW, Wu MH, et al. Thymic neuroendocrine carcinoma and thymoma are both associated with increased risk of extrathymic malignancy: A 20-year review of a single institution. Ann Thorac Surg 2011;91:219-225.
37. Roden AC, Yi ES, Cassivi SD, Jenkins SM, Garces YI, Aubry MC. Clinicopathological features of thymic carcinomas and the impact of histopathological agreement on prognostical studies. Eur J Cardiothorac Surg 2013;43:1131-1139.
38. Verghese ET, den Bakker MA, Campbell A, et al. Interobserver variation in the classification of thymic tumours -A multicentre study using the WHO classification system. Histopathology 2008;53:218-223.
39. Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol 2011;8:199-202.
40. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011;41:1517-1527.
41. Tokunaga T, Hayashi A, Kadota Y, et al. Regulation of Th-POK and Runx3 in T cell development in human thymoma. Autoimmunity 2009;42:653-660.
42. Machens A, Loliger C, Pichlmeier U, Emskötter T, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 1999;91:296-301.
43. Theofilopoulos AN, Dummer W, Kono DH. T cell homeostasis and systemic autoimmunity. J Clin Invest 2001;108:335-340.
44. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
45. Badve S, Goswami C, Gökmen-Polar Y, et al. Molecular analysis of thymoma. PLoS One 2012;7:e42669.
46. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997;17:393-398.
47. Finnish-German AC. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-Type zinc-finger domains. Nat Genet 1997;17:399-403.
48. Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291-297.
49. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006;3:e289.
50. Shiono H, Wong YL, Matthews I, et al. Spontaneous production of anti-IFN-Alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003;15:903-913.
51. Willcox N, Leite MI, Kadota Y, et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008;1132:163-173.
52. Souadjian JV, Silverstein MN, Titus JL. Thymoma and cancer. Cancer 1968;22:1221-1225.
53. Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA 2000;283:1142-1143.
54. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-S265.
55. Weksler B, Nason KS, Mackey D, Gallagher A, Pennathur A. Thymomas and extrathymic cancers. Ann Thorac Surg 2012;93:884-888.
56. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-2715.
57. Roithmaier S, Haydon AM, Loi S, et al. Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience. J Heart Lung Transplant 2007;26:845-849.
58. Marx A, Hohenberger P, Hoffmann H, et al. The autoimmune regulator AIRE in thymoma biology: Autoimmunity and beyond. J Thorac Oncol 2010;5:S266-S272.